Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed primary endometrial carcinoma meeting 1 of the following criteria:

  * Stage III or IV disease according to FIGO staging criteria
  * Recurrent disease that is considered incurable
* Measurable disease

  * A lesion within a previously irradiated field is acceptable as measurable disease only if there has been clear progression since completion of radiotherapy

PATIENT CHARACTERISTICS:

* GOG performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9 g/dL
* Creatinine \< 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min
* ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of liver metastases)
* Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)
* Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)
* Not pregnant or nursing
* Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO
* No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome
* No other invasive malignancy (i.e., breast cancer) within the past 5 years except nonmelanoma skin cancer
* No cardiac disease, including any of the following:

  * Myocardial infarction within the past 6 months
  * NYHA class II-IV heart failure
  * Uncontrolled angina
  * Severe uncontrolled ventricular arrhythmias
  * Clinically significant pericardial disease
  * Acute ischemic or active conduction system abnormalities by ECHO

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy
* No prior cancer therapy that would contraindicate study treatment
* No concurrent investigational agents